Has Surbhi Sidana, MD received payments from drug or device companies?

Yes. Drug and device makers reported $169,543 in general payments to Surbhi Sidana, MD across 177 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Surbhi Sidana, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Surbhi Sidana, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Surbhi Sidana, MD

Hematology · Stanford, CANPI 1972868644

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $148,488 of the $169,543 with a category attached, or 87.6%. It is spread thinly across 19 manufacturers, the largest accounting for just 17.5%. 2025 is the largest year on record at $61,369, more than ten times the $2,327 reported in 2019. Among hematology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$169,543in general payments, 2019–2025

Across 177 payments — averaging $957.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$30K
E.r. Squibb & Sons, L.L.C.$25K
Johnson & Johnson$23K
Janssen Global Services, LLC$21K
Regeneron$18K
Legend Biotech USA Inc.$15K
plus $37K from 13 others

$2,878,006in research payments, 2019–2025

Across 194 payments — averaging $14,835 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$1.6M
Novartis$346K
Bristol Myers Squibb$317K
Gilead$250K
E.r. Squibb & Sons, L.L.C.$206K
National Marrow Donor Program$82K
plus $37K from 2 others

What the payments were for

Consulting fees$148,48888%
Speaking & faculty fees$4,3883%
Grants$840%
Travel & lodging$11,9327%
Food & beverage$4,6503%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	14	$29,722
E.r. Squibb & Sons, L.L.C.	19	$25,468
Johnson & Johnson	32	$23,061
Janssen Global Services, LLC	36	$21,009
Regeneron	16	$17,851
Legend Biotech USA Inc.	15	$15,381
Gilead(2 entities)	6	$13,020
Janssen Scientific Affairs, LLC	6	$7,811
Bristol Myers Squibb	18	$3,475
F. Hoffmann-la Roche AG	4	$3,284
Sanofi	3	$3,020
AbbVie	1	$2,200
Takeda Pharmaceuticals U.S.A., Inc.	1	$1,609
Biolinerx USA, Inc.	1	$1,563
Genentech USA, Inc.	1	$625
AstraZeneca	1	$238
Genentech, Inc.	1	$126
Novartis	1	$61
Janssen Research & Development, LLC	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CARVYKTI$47,197
DARZALEX$37,050
ELREXFIO$27,934
TALVEY$25,339
TECVAYLI$21,215
ABECMA$7,196
Tecartus$3,820
SARCLISA$2,936
LYNOZYFIC$2,909
APHEXDA$1,563
Breyanzi$223

How this compares

$169,543 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.

See all hematology providers in California →

Medicare billing

Part B allowed, 2024

$43,741

Medicare patients

Services billed

281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Atovaquone	18	$7,693
Acyclovir	75	$1,722
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	31	$225
Levofloxacin	11	$145
Ondansetron Hcl	15	$109
Lorazepam	12	$76

Paid to pharmacies, not to this prescriber.

Other hematology in Stanford

Everett MeyerStanford$2.1M
Deepu MadduriStanford$348K
Michaela LiedtkeStanford$112K
Sydney LuStanford$110K
Saurabh DahiyaStanford$94K
David MiklosStanford$90K
Lori MufflyStanford$87K
Ravindra MajetiStanford$58K
Robert NegrinStanford$38K
Rondeep BrarStanford$37K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →